Fig. 5: SYK supports growth and survival of MYD88-mutated lymphoma cells.
From: SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
Impact of SYK knockdown on the cell growth and survival of MYD88-mutated BCWM.1, MWCL-1, and MYD88/CD79B mutated TMD8 ABC DLBCL cells was determined by CellTiter-Glo® luminescent cell viability assay following cell sorting for GFP+ cells at day 5 of lentiviral vector transduction. Cell viability was tracked from day 5 to day 11 following lentiviral transduction (a). Dose–response curves for the SYK inhibitors tamatinib and entospletinib in MYD88-mutated WM (BCWM.1, MWCL-1) and MYD88/CD79B mutated ABC DLBCL (TMD8, HBL-1) cells (b). Studies were performed in triplicate for each experimental set, and representative experimental set of two independent experiments is shown.
